RPMGX
Price
$97.30
Change
-$0.03 (-0.03%)
Updated
Sep 18 closing price
Net Assets
20.82B
SPYGX
Price
$20.56
Change
-$0.16 (-0.77%)
Updated
Sep 18 closing price
Net Assets
940.7M
Interact to see
Advertisement

RPMGX vs SPYGX

RPMGX vs SPYGX Comparison Chart in %
View a ticker or compare two or three
VS
RPMGX vs. SPYGX commentary
Sep 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RPMGX is a Hold and SPYGX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RPMGX has more cash in the bank: 20.8B vs. SPYGX (941M). RPMGX (0.00) and SPYGX (0.00) have matching dividends . RPMGX was incepted earlier than SPYGX: RPMGX (34 years) vs SPYGX (9 years). SPYGX (1.09) is less costly to investors than RPMGX (0.77). SPYGX is a more actively managed with annual turnover of: 85.00 vs. RPMGX (31.50). RPMGX has a lower initial minimum investment than SPYGX: RPMGX (2500) vs SPYGX (100000). RPMGX annual gain was more profitable for investors over the last year : -5.63 vs. SPYGX (-13.14). SPYGX return over 5 years is better than : -13.10 vs. RPMGX (-24.20).
RPMGXSPYGXRPMGX / SPYGX
Total Expense Ratio0.771.0077%
Annual Report Gross Expense Ratio0.771.0971%
Fund Existence34 years9 years-
Gain YTD0.062-11.532-1%
Front LoadN/AN/A-
Min. Initial Investment25001000003%
Min. Initial Investment IRAN/AN/A-
Net Assets20.8B941M2,210%
Annual Yield % from dividends0.000.00-
Returns for 1 year-5.63-13.1443%
Returns for 3 years-0.1973.06-0%
Returns for 5 years-24.20-13.10185%
Returns for 10 years27.75N/A-
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GGOAX11.150.01
+0.09%
Goldman Sachs Mid Cap Growth A
JOHAX29.76-0.01
-0.03%
JOHCM International Select Investor
PRHSX94.44-0.31
-0.33%
T. Rowe Price Health Sciences
THMEX16.85-0.07
-0.41%
CCT Thematic Equity Institutional
BRSYX16.90-0.09
-0.53%
MFS Blended Research Small Cap Eq R6